King Pharmaceuticals KG Lease Liability Payments - Remainder of Fiscal Year

Lease Liability Payments - Remainder of Fiscal Year at other companies

SiriusPointSPNT

$5.5M+5.8%

Silvercrest Asset Management GroupSAMG

$100K+6.4%

Community Financial SystemCBU

$11.82M+9.4%

LazardLAZ

$80.67M+4.1%

W.R. BerkleyWRB

——

Other financials

Income statement

See full

Revenue$10.2M+1,112%

Net income-$7.4M-1,786%

EPS (diluted)-$0.96-586%

Balance sheet

See full

Cash & equivalents$62.2M+1,724%

Total debt$176.7M—

Total equity$121.4M+2,773%

Total assets$964.2M—

Cash flow

See full

Operating cash flow-$15.1M-1,628%

Valuation

See full

Market cap$70.42M-71.3%

Enterprise value$184.93M-52.3%

P/E1.2×—

P/S1.6×-27.7×

Profitability

See full

Net margin131.5%—

Returns & leverage

See full

Return on equity90.8%—

Debt / equity1.5×—

Where this comes from

Reported directly by King Pharmaceuticals in its filing.

Tagged under the XBRL concept us-gaap:LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths.

The official record: King Pharmaceuticals’s 10-Q, filed May 8, 2026, on SEC EDGAR. View the filing →

Ask your AI about King Pharmaceuticals's lease liability payments - remainder of fiscal year.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI

Claude

Questions, answered.

What is King Pharmaceuticals's lease liability payments - remainder of fiscal year?: King Pharmaceuticals (KG) reported lease liability payments - remainder of fiscal year of $366K in Q1 2026.
What does lease liability payments - remainder of fiscal year mean?: The contractual cash obligations for operating and finance leases due within the remaining months of the current fiscal year. This provides a short-term view of the company's fixed lease commitments. It is a critical component for assessing near-term liquidity and cash flow requirements.